Product
Help
Pricing
About
Jobs
Log in
Get started
Institution
Add to collection
ARON Research Foundation ETS
Homepage:
aronresearchfoundation.com
Alternate name:
ARON Research Foundation
ROR:
01tr5ad93
OpenAlex ID:
I4405264403
The Prognostic Role of Baseline and Early Dynamics of Peripheral Blood Cell Ratios in Metastatic Renal Cell Carcinoma Patients Treated With Nivolumab
2026
·
ONDREJ FIALA
, MICHAELA TKADLECOVA
, et al.
·
In Vivo
·
5
PDF
Belzutifan monotherapy and combination therapies in renal cell carcinoma: a clinical trial perspective from the ARON working group
2026
·
Concetta Calabrò
, Francesco Ciccimarra
, et al.
·
Expert Opinion on Pharmacotherapy
·
4
Microplastics as both a driver of genitourinary cancers and a deliverer of treatments
2026
·
Kannan Sridharan
, Brigida Anna Maiorano
, et al.
·
Communications Medicine
·
3
PDF
Comprehensive Transcriptome and miRNome Profiling in Metachronous Colorectal Liver Metastasis: Insight Into the Prognostic and Molecular Subtypes
2025
·
Bhavana Hemantha Rao
, Veronika Boušková
, et al.
·
Laboratory Investigation
·
3
Stereological quantification of tumor infiltrating immune cells as predictor of immunotherapy in metastatic melanoma
2025
·
Lenka Vaňková
, Jiří Polívka
, et al.
·
Experimental and Molecular Pathology
·
2
Global Real‐World Outcomes of Olaparib in Metastatic Castration‐Resistant Prostate Cancer Patients With Homologous Recombination Repair Alterations
2026
·
Lorena Incorvaia
, Daniele Santini
, et al.
·
International Journal of Cancer
·
1
PDF
Real-world incidence of G3-G4 adverse events with enfortumab vedotin in patients with advanced urothelial carcinoma (ARON-2EV study)
2026
·
Patrizia Giannatempo
, Shilpa Gupta
, et al.
·
Scientific Reports
·
1
PDF
Nivolumab in previously treated metastatic renal cell carcinoma: real-world data from the Czech Republic and Slovakia
2026
·
Ondřej Fiala
, Michaela Tkadlecová
, et al.
·
Frontiers in Immunology
·
1
PDF
Baseline and early changes in eosinophil count and neutrophil-to-eosinophil ratio predict outcomes in metastatic renal cell carcinoma treated with nivolumab
2025
·
Ondřej Fiala
, Katarína Rejleková
, et al.
·
Scientific Reports
·
1
PDF
Optimized pharmacotherapeutic management of immune checkpoint inhibitor treatment in metastatic clear-cell renal cell carcinoma
2026
·
Kannan Sridharan
, Giandomenico Roviello
, et al.
·
Expert Opinion on Pharmacotherapy
Sex-based differences in clinical outcomes of enfortumab vedotin and NECTIN-4 expression in urothelial cancer
2026
·
Tarek Taha
, Ayelet Alpert
, et al.
·
Nature Communications
PDF
Real‐World HRR Testing Pathways and Patterns of Detected Alterations in Prostate Cancer From the Multinational ARON‐3 Study
2026
·
Lorena Incorvaia
, Veronica Mollica
, et al.
·
The Prostate
Early dynamics of eosinophils and the neutrophil-to-lymphocyte ratio are associated with severe immune-related adverse events during nivolumab therapy for metastatic renal cell carcinoma
2026
·
Ondřej Fiala
, Jan Králíček
, et al.
·
Frontiers in Immunology
PDF
Global disparities in the availability and reimbursement of systemic therapies for renal cell carcinoma: results of the International ARON-AID Survey
2026
·
Yuksel Urun
, Kannan Sridharan
, et al.
·
The Oncologist
PDF
Disitamab vedotin in urothelial carcinoma patients: a clinical trial perspective from ARON working group
2026
·
Concetta Calabrò
, Francesco Ciccimarra
, et al.
·
Expert Review of Clinical Pharmacology
Nutritional status and survival outcomes in patients with cancer treated with immune checkpoint inhibitors: The ARON-MOUSEION-20 systematic review and meta-analysis
2026
·
Chiara Paciolla
, Elsa Vitale
, et al.
·
Clinical Nutrition ESPEN
Machine learning integrated explainable artificial intelligence in predicting toxicities of enfortumab vedotin in urothelial carcinoma: an exploratory study
2026
·
Kannan Sridharan
, Mattia Alberto Di Civita
, et al.
·
Expert Review of Anticancer Therapy
Theranostics in the management of prostate cancer: from concept to clinical practice
2026
·
Kannan Sridharan
, Teresa Alonso-Gordoa
, et al.
·
Expert Review of Clinical Pharmacology
Triplet Therapy in Metastatic Clear Cell Renal Cell Carcinoma: Time to Abandon Empiric, Biomarker-unselected Intensification?
2026
·
Javier Molina-Cerrillo
, Victoria Gómez Dos Santos
, et al.
·
European Urology Oncology
Machine learning-integrated explainable artificial intelligence for survival prediction in urothelial carcinoma with enfortumab vedotin: an exploratory real-world analysis
2026
·
Kannan Sridharan
, Ondrej Fiala
, et al.
·
Expert Opinion on Biological Therapy
Sex-based analysis of first-line immune-based combinations in intermediate/poor-risk papillary, chromophobe, and unclassified renal cell carcinoma: an ARON-1 subanalysis
2026
·
Paola I. Valdez-Sandoval
, Evelyn L. Beas-Lozano
, et al.
·
Frontiers in Oncology
PDF
Embarking on a new era in high-risk biochemical recurrent prostate cancer: redefining early systemic intervention
2026
·
Martina Izzi
, Andrea Lapucci
, et al.
·
Pharmacology & Therapeutics
PDF
Beyond prostate-specific antigen: ctDNA as an early compass for treatment adaptation in metastatic prostate cancer
2026
·
Giandomenico Roviello
, Matteo Santoni
, et al.
·
Signal Transduction and Targeted Therapy
PDF
Myositis in cancer patients receiving immune checkpoint inhibitors: the ARON-MOUSEION-017 systematic review and meta-analysis
2026
·
Elsa Vitale
, Gerardo Cazzato
, et al.
·
Expert Opinion on Drug Safety
Baseline Disease Characteristics and Platinum Sensitivity as Predictors of Outcomes in Sequential Therapy with Platinum-Based Chemotherapy, Avelumab Maintenance, and Enfortumab Vedotin in Advanced Urothelial Carcinoma (ARON-2EV Study)
2026
·
Mimma Rizzo
, Sebastiano Buti
, et al.
·
Targeted Oncology
PDF
Show more works
View as search
Works count:
36
Citation count:
28
Year
Topic
Type
